Paradigm Genetics Appoints Susan Harlander, Ph.D., to Its Board of Directors

Apr 26, 2001, 01:00 ET from Paradigm Genetics, Inc.

    RESEARCH TRIANGLE PARK, N.C., April 26 /PRNewswire/ --
     Paradigm Genetics, Inc. (Nasdaq:   PDGM), a functional genomics company, has
 named Susan Harlander, Ph.D., 52, to its Board of Directors.  Harlander is
 currently president of BIOrational Consultants, Inc., a consulting firm
 specializing in food and biotechnology issues facing all aspects of the food
 supply chain.
     "Susan Harlander is a highly respected authority in the area of food
 science and human nutrition," said John A. Ryals, Ph.D., Chief Executive
 Officer and President of Paradigm Genetics.  "She will add a new dimension to
 our board as we explore potential uses of plants and fungi for human
 nutrition.  The nutrition market is growing very rapidly, and it's a natural
 progression for Paradigm to enter it."
     "I am very pleased to join Paradigm Genetics in its effort to apply
 functional genomics to human nutrition," said Harlander.  "As the world's
 population continues to grow and to age, the human food supply will be
 stretched and tested in ways we haven't yet experienced.  And people will be
 looking for novel nutrition choices to prolong life.  I believe Paradigm's
 approach to gene function discovery and metabolic profiling will help us
 successfully face those future challenges."
     Harlander currently serves as a member of the USDA's National Agricultural
 Research, Extension, Education and Economics Advisory Board, the American
 Society of Plant Physiologists' Education Foundation board of directors, and
 the Institute of Food Technologists' Foundation Board.  She has served on
 numerous government agency advisory committee's including the FDA's Food
 Advisory Committee, USDA's Agricultural Biotechnology Research Advisory
 Committee, USDA's Science and Education Advisory Committee and the NRC's Board
 on Agriculture and Food Chemicals Codex Committees.
     Before starting BIOrational Consultants, Harlander spent five years at The
 Pillsbury Company, most recently as vice president of biotechnology
 development and agricultural research.  Prior to that, she worked as director
 of dairy foods research and development for Land O'Lakes, Inc.  Harlander was
 a faculty member in the Department of Food Science and Nutrition at the
 University of Minnesota.  Her research there involved genetic modification of
 dairy starter cultures and production of secondary metabolites by plant tissue
 culture.  Harlander received her master's degree in Microbiology and Ph.D. in
 Food Science at the University of Minnesota.
 
     About Paradigm Genetics
     Paradigm Genetics is industrializing the process of gene function
 discovery for four major sectors of the global economy: human health,
 nutrition, crop production and industrial products.  The company has designed
 the GeneFunction Factory(TM) - an integrated, rapid, industrial-scale
 laboratory through which it discovers gene function.  Paradigm and its
 strategic partners intend to develop novel products using information
 developed with the GeneFunction Factory(TM).  Paradigm's GeneFunction
 Factory(TM) is based on a state of the art phenomics platform integrated with
 metabolic profiling and gene expression profiling technologies.  The backbone
 of the GeneFunction Factory(TM) is the company's proprietary
 FunctionFinder(TM) bioinformatics system, used to collect, store, analyze and
 retrieve information.  For more information, visit www.paradigmgenetics.com.
 
     This press release contains forward-looking statements, including
 statements regarding Paradigm's ability to successfully develop its
 GeneFunction Factory(TM) and other technologies; Paradigm's ability to
 industrialize the process of gene function discovery for four major sectors of
 the global economy: human health, nutrition, crop production and industrial
 products; the prospects of Paradigm and its partners to develop products;
 Paradigm's ability to meet or exceed the expectations of its partners; as well
 as Paradigm's prospects for growth and innovation. Such statements are based
 on management's current expectations and are subject to a number of risks,
 factors and uncertainties that may cause actual results, events and
 performance to differ materially from those referred to in the forward-looking
 statements.  These risks include, but are not limited to, Paradigm's early
 stage of development, history of net losses, technological and product
 development uncertainties, reliance on research collaborations, uncertainty of
 additional funding and ability to protect its patents and proprietary rights.
 These and other risks are identified in Paradigm's report on Form 10-Q for the
 quarter ended September 30, 2000, and on Form 10-K for the year ended December
 31, 2000, filed with the Securities and Exchange Commission.
 
     GeneFunction Factory(TM) and FunctionFinder(TM) are U.S. trademarks of
 Paradigm Genetics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X85123375
 
 

SOURCE Paradigm Genetics, Inc.
    RESEARCH TRIANGLE PARK, N.C., April 26 /PRNewswire/ --
     Paradigm Genetics, Inc. (Nasdaq:   PDGM), a functional genomics company, has
 named Susan Harlander, Ph.D., 52, to its Board of Directors.  Harlander is
 currently president of BIOrational Consultants, Inc., a consulting firm
 specializing in food and biotechnology issues facing all aspects of the food
 supply chain.
     "Susan Harlander is a highly respected authority in the area of food
 science and human nutrition," said John A. Ryals, Ph.D., Chief Executive
 Officer and President of Paradigm Genetics.  "She will add a new dimension to
 our board as we explore potential uses of plants and fungi for human
 nutrition.  The nutrition market is growing very rapidly, and it's a natural
 progression for Paradigm to enter it."
     "I am very pleased to join Paradigm Genetics in its effort to apply
 functional genomics to human nutrition," said Harlander.  "As the world's
 population continues to grow and to age, the human food supply will be
 stretched and tested in ways we haven't yet experienced.  And people will be
 looking for novel nutrition choices to prolong life.  I believe Paradigm's
 approach to gene function discovery and metabolic profiling will help us
 successfully face those future challenges."
     Harlander currently serves as a member of the USDA's National Agricultural
 Research, Extension, Education and Economics Advisory Board, the American
 Society of Plant Physiologists' Education Foundation board of directors, and
 the Institute of Food Technologists' Foundation Board.  She has served on
 numerous government agency advisory committee's including the FDA's Food
 Advisory Committee, USDA's Agricultural Biotechnology Research Advisory
 Committee, USDA's Science and Education Advisory Committee and the NRC's Board
 on Agriculture and Food Chemicals Codex Committees.
     Before starting BIOrational Consultants, Harlander spent five years at The
 Pillsbury Company, most recently as vice president of biotechnology
 development and agricultural research.  Prior to that, she worked as director
 of dairy foods research and development for Land O'Lakes, Inc.  Harlander was
 a faculty member in the Department of Food Science and Nutrition at the
 University of Minnesota.  Her research there involved genetic modification of
 dairy starter cultures and production of secondary metabolites by plant tissue
 culture.  Harlander received her master's degree in Microbiology and Ph.D. in
 Food Science at the University of Minnesota.
 
     About Paradigm Genetics
     Paradigm Genetics is industrializing the process of gene function
 discovery for four major sectors of the global economy: human health,
 nutrition, crop production and industrial products.  The company has designed
 the GeneFunction Factory(TM) - an integrated, rapid, industrial-scale
 laboratory through which it discovers gene function.  Paradigm and its
 strategic partners intend to develop novel products using information
 developed with the GeneFunction Factory(TM).  Paradigm's GeneFunction
 Factory(TM) is based on a state of the art phenomics platform integrated with
 metabolic profiling and gene expression profiling technologies.  The backbone
 of the GeneFunction Factory(TM) is the company's proprietary
 FunctionFinder(TM) bioinformatics system, used to collect, store, analyze and
 retrieve information.  For more information, visit www.paradigmgenetics.com.
 
     This press release contains forward-looking statements, including
 statements regarding Paradigm's ability to successfully develop its
 GeneFunction Factory(TM) and other technologies; Paradigm's ability to
 industrialize the process of gene function discovery for four major sectors of
 the global economy: human health, nutrition, crop production and industrial
 products; the prospects of Paradigm and its partners to develop products;
 Paradigm's ability to meet or exceed the expectations of its partners; as well
 as Paradigm's prospects for growth and innovation. Such statements are based
 on management's current expectations and are subject to a number of risks,
 factors and uncertainties that may cause actual results, events and
 performance to differ materially from those referred to in the forward-looking
 statements.  These risks include, but are not limited to, Paradigm's early
 stage of development, history of net losses, technological and product
 development uncertainties, reliance on research collaborations, uncertainty of
 additional funding and ability to protect its patents and proprietary rights.
 These and other risks are identified in Paradigm's report on Form 10-Q for the
 quarter ended September 30, 2000, and on Form 10-K for the year ended December
 31, 2000, filed with the Securities and Exchange Commission.
 
     GeneFunction Factory(TM) and FunctionFinder(TM) are U.S. trademarks of
 Paradigm Genetics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X85123375
 
 SOURCE  Paradigm Genetics, Inc.